South America News
Filter News
Found 1,574 articles
-
Procaps Group to Acquire Grupo Somar (including Química y Farmacia, Gelcaps and related entities) from Advent International, gaining an important presence in Mexico, the Region's Second Largest Market
5/17/2022
Procaps Group, a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced it has entered into a definitive agreement to acquire Grupo Somar from Advent International, one of the world’s largest private equity investors.
-
Rhino Biotech to Present at the Planet Microcap Showcase
5/4/2022
Rhino Biotech Limited, a Biotech Company, announced it will be presenting at the SNN Network Planet MicroCap Showcase on May 4, 2022 at 2:30 p.m. Pacific Time.
-
Genomma Lab Internacional Reports First Quarter 2022 Results
4/27/2022
Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter ended March 31, 2022.
-
Biosimilar Solutions Initiates Registrational Clinical Trial for Biosimilar Version Neulasta
4/13/2022
OcyonBio, LLC's client Biosimilar Solutions, Inc., announces it has started its registrational clinical trials for the biosimilar version of Neulasta Filgrastim, a granulocyte-colony stimulating factor.
-
CytoImmune Therapeutics, Inc. Opens the Company’s Clinical Cell Manufacturing Facility in Toa Baja
3/24/2022
CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer cell-based cancer therapies, announced the opening of the Company’s clinical cell manufacturing facility in Toa Baja, which was celebrated with a visit from the Governor of Puerto Rico, Pedro R. Pierluisi.
-
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2022
3/17/2022
Pharma-Bio Serv, Inc. announced that revenues for the quarter ended January 31, 2022 were approximately $5.0 million, an increase of approximately $0.5 million when compared to the same period last year.
-
Pharma-Bio Serv Announces Full Year Results and Declares a Special Dividend
2/11/2022
Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), today announced that revenues for the year ended October 31, 2021 were approximately $20.1 million, a decrease of approximately $1.4 million when compared to last year.
-
Procaps Group Announces Appointment of Melissa Angelini as Investor Relations Director
1/28/2022
Procaps Group, a leading integrated international healthcare and pharmaceutical company, announced the appointment of Melissa Angelini as Investor Relations Director, effective February 1, 2022.
-
As Omicron continues to dominate globally, research is coming in every day on this highly contagious variant of SARS-CoV-2.
-
Procaps Group Acquires 1st U.S.-Based Softgel Production Facility and Pharmaceutical R&D Center to Expand Global Growth of its iCDMO Business Unit
1/12/2022
Procaps Group, a leading integrated international healthcare and pharmaceutical company, announced the closing of an asset purchase agreement to acquire an 86,000 sq. ft.
-
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
11/30/2021
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘Anvisa’) has granted an exceptional authorisation for Illuccix® (TLX591-CDx) the Company’s lead prostate cancer imaging product.
-
Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market
11/22/2021
Sorrento Therapeutics, Inc. announced its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with a leading local distributor for the sale and distribution of up to 5 million COVI-STIX™ tests for the Mexican market.
-
Procaps Group Reports Record Third Quarter 2021 Financial Results
11/19/2021
Procaps Group, a leading integrated international healthcare and pharmaceutical company, announced its financial results for the third quarter ended September 30, 2021.
-
Bioceres Crop Solutions Announces Regulatory Approval of Drought Tolerant HB4® Wheat by Brazil’s CTNBio
11/11/2021
bBioceres Crop Solutions Corp., a fully integrated global provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has received import approval of the Company’s HB4 Wheat flour for animal and human consumption from Brazil’s Ministry of Agriculture, Livestock and Food Supply.
-
The Delta variant is the deadliest variant of the coronavirus, and according to the CDC, this variant has the highest transmission rate yet.
-
miR Scientific and Puerto Rico Government team up for Prostate Cancer Prevention Day, to battle the number one cause of cancer-related death among men in the island
9/1/2021
miR Scientific, LLC, a healthcare company focused on transforming global cancer management, the Governor of Puerto Rico, Pedro Pierluisi, and the Puerto Rico Health Insurance Administration ("ASES") join forces today to officially make September 1 "Prostate Cancer Prevention Day".
-
Dasa expands partnership with SOPHiA GENETICS for the first decentralized cancer biomarker detection solution in Latin America
8/24/2021
Dasa, the largest integrated healthcare network in Brazil, has chosen to expand upon its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to offer the first decentralized HRD (Homologous recombination deficiency) analytics solution in Latin America.
-
With business taking him throughout North and South America, Asia, and Europe, he’s learned to adapt and appreciate the nuances of a multicultural environment.
-
VisionQuest Uses Artificial Intelligence to Screen 40,000 Patients for Diabetic Retinopathy
6/15/2021
VisionQuest Biomedical Inc. announces that the company has used the EyeStar artificial intelligence software to screen over 40,000 patients for diabetic retinopathy at the Clínicas del Azúcar.
-
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2021
6/14/2021
Pharma-Bio Serv, Inc. announced revenues for the three and six months ended April 30, 2021 were $5,042,000 and $9,530,000, respectively, a decrease of approximately $606,000 and $731,000, respectively, when compared to the same periods last year.